Longitudinal Outcomes from Conservative Management of Cervical Cancer Associated Ureteral Obstruction

Urology. 2021 Dec:158:208-214. doi: 10.1016/j.urology.2021.09.007. Epub 2021 Sep 25.

Abstract

Objective: To identify predictors of hydronephrosis (HN) resolution and HN treatment failure. HN is a common comorbid condition with cervical cancer (CCa). Treatments for CCa continue to improve and long-term management strategies of HN are becoming increasingly necessary.

Methods: A query of a single hospital (2004 - 2019) ICD-9 and CPT codes was made to develop a cohort of CCa patients with HN. A retrospective review was performed. The effects of patient, renal/HN, and cancer covariates on time to HN treatment failure, treatment complications and time to HN resolution were evaluated using logistic regression and competing risk Cox regression models.

Results: Of the 1670 women treated for CCa during the study period, 179 (10.7%) developed HN (n = 72 (40%) bilateral), 78 (44%) at time of CCa diagnosis and 101 (56%) as a result of treatment, of which 145 (81%) underwent initial treatment with a PCN (n = 77, 53%) or US (n = 68, 47%). Complication rates were similar between PCN (56%) and US (61%) when adjusting for treatment time. Initial treatment failure was more likely with US vs PCN (HR 3.2, P <0.01). HN resolution (n = 32, 22%) without reconstruction was predicted by HN concurrent with CCa diagnosis (HR 3.1, P <0.01) and bilateral HN (HR 0.2, P <0.01).

Conclusion: CCa associated HN has a resolution rate of only 19% at 12 months. Those presenting with HN after CCa treatment are less likely to resolve without reconstruction. PCN and US have similar complication rates but initial US placement has a nearly three times increased risk of failing than PCN.

MeSH terms

  • Conservative Treatment*
  • Female
  • Humans
  • Hydronephrosis / etiology*
  • Hydronephrosis / therapy*
  • Middle Aged
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome
  • Ureteral Obstruction / etiology*
  • Ureteral Obstruction / therapy*
  • Uterine Cervical Neoplasms / complications*